Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.61
+0.01 (0.18%)
Aug 26, 2026, 4:00 PM EDT - Market closed
Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Savara Inc.
| Country | United States |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Matthew Pauls |
Contact Details
Address: The Tannery, Suite 200 Yardley, Pennsylvania 19067 United States | |
| Website | savarapharma.com |
Stock Details
| Ticker Symbol | SVRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001160308 |
| CUSIP Number | 805111101 |
| ISIN Number | US8051111016 |
| Employer ID | 84-1318182 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Pauls J.D., M.B.A. | Chairman and Chief Executive Officer |
| Robert Matthew Lutz M.B.A. | Chief Operating Officer and Chief Financial Officer |
| Dr. Yasmine Wasfi M.D., Ph.D. | Chief Medical Officer |
| Kate McCabe J.D. | Chief Legal Officer |
| Megan Carpenter | Chief People Officer |
| Anne Erickson | Chief Business and Corporate Affairs Officer |
| Brian Maurer | Head of Clinical Operations |
| Charles LaPree | Executive Vice President and Head of Global Regulatory Affairs |
| Dr. Brian Robinson M.D. | Executive Vice President of Global Medical Affairs |
| Dr. Siddharth J. Advant Ph.D. | Executive Vice President of Global Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Jun 22, 2026 | 144 | Filing |
| Jun 8, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 13, 2026 | 8-K | Current Report |